IFNB1 and myeloid sarcoma: Limitations of our study are (i) the lack of a control group of MS-patients that do not respond to treatment with IFNβ, missing information on correlations of the vaccine-response with (ii) a potential IFNβ-induced lymphopenia and (iii) the MHC haplotype status of our study subjects.